Search

Displaying results 2351 - 2360 of 8696 in total
  1. Drug

    Lovastatin

    go.drugbank.com/drugs/DB00227
    ApprovedInvestigational

    [A181084] Elevated cholesterol levels, and in particular, elevated low-density lipoprotein (LDL) levels, are an important risk factor for the development of CVD. … as well as the need for surgical revascularization or angioplasty following a heart attack.

    Categories: Hypolipidemic Agents Indicated for Hyperlipidemia, Cytochrome P-450 SubstratesProducts: Ran-lovastatin
  2. Drug

    Foreskin fibroblast (neonatal)

    go.drugbank.com/drugs/DB10770
    Approved

    Dermagraft has only been available in the United States as an investigational device (IDE). Dermagraft for the treatment of diabetic foot ulcers was approved for sale in Canada in 1997. … Foreskin fibroblast-like stromal cells (FDSCs) are progenitors isolated from human tissue that can differentiate into various cell types [A32660].

  3. Drug

    Dibotermin alfa

    go.drugbank.com/drugs/DB11639
    ApprovedInvestigational

    Dibotermin alfa was approved by the EMA in 2002 as Inductos for implantation matrix. In 2004, it was approved by the FDA and is marketed as Infuse. … Through enhancing osteogenesis at the site of implantation, dibotermin alfa accelerates the healing of open tibial shaft fractures and reduces the need for secondary intervention [A31945].

    Categories: Drugs for Treatment of Bone Diseases
  4. Drug

    Aminosalicylic acid

    go.drugbank.com/drugs/DB00233
    ApprovedInvestigational

    An antitubercular agent often administered in association with isoniazid. The sodium salt of the drug is better tolerated than the free acid.

    Synonyms: p-aminosalicylic acidCategories: Antiinfectives for Systemic Use, Drugs for Treatment of Tuberculosis
  5. Drug

    VidPrevtyn Beta

    go.drugbank.com/drugs/DB16427
    Approved

    [A245829,L49696] In October 2022, VidPrevtyn Beta was approved in the European Union for use as a booster dose in patients who have previously received a COVID-19 vaccine.[L49691] … VidPrevtyn Beta is an adjuvanted, recombinant COVID-19 vaccine developed collaboratively by GlaxoSmithKline (GSK) and Sanofi Pasteur.

  6. Drug

    Homatropine methylbromide

    go.drugbank.com/drugs/DB00725
    Approved

    It can be used together with antacids or other medicine in the treatment of peptic ulcer. It may also be used to prevent nausea, vomiting, and motion sickness. … Homatropine methylbromide is a quaternary ammonium muscarinic acetylcholine receptor antagonist belonging to the group of medicines called anti-muscarinics.

    Categories: Drugs for Functional Gastrointestinal Disorders
  7. Drug

    Olsalazine

    go.drugbank.com/drugs/DB01250
    Approved

    [A257063] It was first developed for delivering mesalamine to the colon without the use of [sulfapyridine]. … Olsalazine is an aminosalicylate and a prodrug of [mesalamine] (5-aminosalicylic acid, 5-ASA).

  8. Drug

    Dordaviprone

    go.drugbank.com/drugs/DB14844
    ApprovedInvestigational

    [A274391] Dordaviprone has several modes of action, including the activation of mitochondrial caseinolytic protease P (ClpP), antagonism of the dopamine D2 receptor,[L53833] activation of Activating Transcription … [L53838] It is used to treat patients with diffuse midline glioma harboring an H3 K27M mutation.

    Categories: Cytochrome P-450 CYP1A2 Inhibitors, Cytochrome P-450 CYP2B6 Inducers
  9. Drug

    Sulfasalazine

    go.drugbank.com/drugs/DB00795
    ApprovedInvestigational

    [L39065, A255582] Metabolized by intestinal bacteria, sulfasalazine is broken down into [mesalazine] and [sulfapyridine], 2 compounds that carry out the main pharmacological activity of sulfasalazine. … Sulfasalazine is an anti-inflammatory drug structurally related to salicylates and other non-steroidal anti-inflammatory drugs.

    Synonyms: 5-(p-(2-Pyridylsulfamyl)phenylazo)salicylic acid, 5-((p-(2-Pyridylsulfamoyl)phenyl)azo)salicylic acid
  10. Drug

    Ripretinib

    go.drugbank.com/drugs/DB14840
    ApprovedInvestigational

    Ripretinib, also known as Qinlock, is manufactured by Deciphera Pharmaceuticals and was initially approved by the FDA on May 15, 2020. … Ripretinib is a kinase inhibitor used for the treatment of advanced gastrointestinal stromal tumor (GIST) that has not adequately responded to other kinase inhibitors such as [sunitinib] and [imatinib]

    Categories: Stem Cell Factor (KIT) Receptor Inhibitors, P-glycoprotein inhibitors